Suppr超能文献

心力衰竭中的甲状腺功能及其对死亡率的影响。

Thyroid function in heart failure and impact on mortality.

作者信息

Mitchell Judith E, Hellkamp Anne S, Mark Daniel B, Anderson Jill, Johnson George W, Poole Jeanne E, Lee Kerry L, Bardy Gust H

出版信息

JACC Heart Fail. 2013 Feb;1(1):48-55. doi: 10.1016/j.jchf.2012.10.004.

Abstract

OBJECTIVES

The aim of this study was to investigate whether patients with systolic heart failure (HF) and abnormal thyroid function are at increased risk for death.

BACKGROUND

Thyroid hormone homeostasis is vital to the optimal functioning of the cardiovascular system, but an independent prognostic effect of thyroid abnormalities in patients with HF has not been established.

METHODS

In SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), which randomized patients with ischemic or nonischemic HF to placebo or amiodarone or implantable cardioverter-defibrillator therapy, thyroid-stimulating hormone (TSH) was measured at baseline and at 6-month intervals throughout the 5-year study.

RESULTS

Of 2,225 patients, the majority (87%) had normal TSH levels (0.3 to 5.0 μU/ml) at baseline, 12% had values suggestive of hypothyroidism, and 1% had values consistent with hyperthyroidism. Compared with euthyroid patients, those hypothyroid at baseline were older and included more women and Caucasians (all p values <0.05). Over the median follow-up period of 45.5 months, among patients euthyroid at baseline, 89 developed abnormally low TSH levels, and 341 developed abnormally high values. Patients randomized to amiodarone (median dose 300 mg) had an elevated risk for developing abnormal TSH levels compared with implantable cardioverter-defibrillator therapy or placebo (p < 0.0001). Patients with baseline or new-onset abnormal thyroid function had a higher mortality than those with normal thyroid function, even after controlling for other known mortality predictors (hazard ratio: 1.58; 95% confidence interval: 1.29 to 1.94; p < 0.0001 for hypothyroid; hazard ratio: 1.85; 95% confidence interval: 1.21 to 2.83; p = 0.0048 for hyperthyroid). Implantable cardioverter-defibrillator benefit did not vary with thyroid function.

CONCLUSIONS

Abnormal thyroid function in patients with symptomatic HF and ejection fractions ≤35% is associated with significantly increased risk for death, even after controlling for known mortality predictors.

摘要

目的

本研究旨在调查收缩性心力衰竭(HF)且甲状腺功能异常的患者死亡风险是否增加。

背景

甲状腺激素稳态对心血管系统的最佳功能至关重要,但HF患者甲状腺异常的独立预后影响尚未确定。

方法

在心力衰竭猝死试验(SCD-HeFT)中,将缺血性或非缺血性HF患者随机分为接受安慰剂、胺碘酮或植入式心脏复律除颤器治疗,在为期5年的研究中,于基线及此后每6个月测量一次促甲状腺激素(TSH)。

结果

2225例患者中,大多数(87%)在基线时TSH水平正常(0.3至5.0 μU/ml),12%的患者TSH值提示甲状腺功能减退,1%的患者TSH值符合甲状腺功能亢进。与甲状腺功能正常的患者相比,基线时甲状腺功能减退的患者年龄更大,女性和白种人更多(所有p值均<0.05)。在45.5个月的中位随访期内,基线时甲状腺功能正常的患者中,89例出现TSH水平异常降低,341例出现TSH水平异常升高。与植入式心脏复律除颤器治疗或安慰剂相比,随机接受胺碘酮治疗(中位剂量300 mg)的患者出现TSH水平异常的风险升高(p<0.0001)。即使在控制了其他已知的死亡预测因素后,基线或新发甲状腺功能异常的患者死亡率仍高于甲状腺功能正常的患者(风险比:1.58;95%置信区间:1.29至1.94;甲状腺功能减退患者p<0.0001;风险比:1.85;95%置信区间:1.21至2.83;甲状腺功能亢进患者p=0.0048)。植入式心脏复律除颤器的获益不受甲状腺功能的影响。

结论

有症状的HF且射血分数≤35%的患者,即使在控制了已知的死亡预测因素后,甲状腺功能异常仍与显著增加的死亡风险相关。

相似文献

1
Thyroid function in heart failure and impact on mortality.
JACC Heart Fail. 2013 Feb;1(1):48-55. doi: 10.1016/j.jchf.2012.10.004.
2
Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure).
JACC Heart Fail. 2014 Feb;2(1):35-40. doi: 10.1016/j.jchf.2013.07.008. Epub 2014 Jan 25.
5
Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.
J Am Coll Cardiol. 2020 Jul 28;76(4):405-415. doi: 10.1016/j.jacc.2020.05.061.
6
Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.
Ont Health Technol Assess Ser. 2005;5(14):1-74. Epub 2005 Sep 1.
7
Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Circulation. 2007 May 22;115(20):2637-41. doi: 10.1161/CIRCULATIONAHA.106.661397. Epub 2007 May 7.
8
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
N Engl J Med. 2005 Jan 20;352(3):225-37. doi: 10.1056/NEJMoa043399.
9
SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death.
Heart Rhythm. 2015 Oct;12(10):2058-66. doi: 10.1016/j.hrthm.2015.06.030. Epub 2015 Jun 19.
10
Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study.
J Am Coll Cardiol. 2008 Apr 1;51(13):1277-82. doi: 10.1016/j.jacc.2007.11.065.

引用本文的文献

1
Role of thyroid function in non-basal ganglia intracerebral hemorrhage prognosis.
J Endocrinol Invest. 2025 May 15. doi: 10.1007/s40618-025-02603-7.
2
Thyroid and cardiovascular diseases.
Turk J Med Sci. 2024 Oct 1;54(7):1420-1427. doi: 10.55730/1300-0144.5927. eCollection 2024.
3
Nanoscale organization of cardiac calcium channels is dependent on thyroid hormone status.
Am J Physiol Heart Circ Physiol. 2024 Nov 1;327(5):H1309-H1326. doi: 10.1152/ajpheart.00272.2024. Epub 2024 Oct 4.
4
Associations between peripheral thyroid sensitivity and all-cause and cardiovascular mortality in the US adults with metabolic syndrome.
Front Med (Lausanne). 2024 Sep 11;11:1460811. doi: 10.3389/fmed.2024.1460811. eCollection 2024.
5
Sex difference in human diseases: mechanistic insights and clinical implications.
Signal Transduct Target Ther. 2024 Sep 10;9(1):238. doi: 10.1038/s41392-024-01929-7.
6
Cardiac manifestations in hyperthyroidism.
Rev Cardiovasc Med. 2022 Apr 11;23(4):136. doi: 10.31083/j.rcm2304136. eCollection 2022 Apr.
9
SGLT2 inhibitor as a potential therapeutic approach in hyperthyroidism-induced cardiopulmonary injury in rats.
Pflugers Arch. 2024 Jul;476(7):1125-1143. doi: 10.1007/s00424-024-02967-4. Epub 2024 May 3.
10
The genetic association between hyperthyroidism and heart failure: a Mendelian randomization study.
Front Endocrinol (Lausanne). 2024 Apr 12;15:1344282. doi: 10.3389/fendo.2024.1344282. eCollection 2024.

本文引用的文献

1
Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts.
Circulation. 2012 Aug 28;126(9):1040-9. doi: 10.1161/CIRCULATIONAHA.112.096024. Epub 2012 Jul 19.
2
Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults.
J Am Coll Cardiol. 2012 Aug 21;60(8):730-7. doi: 10.1016/j.jacc.2012.03.047. Epub 2012 Jun 20.
3
Subclinical hyperthyroidism and the risk of coronary heart disease and mortality.
Arch Intern Med. 2012 May 28;172(10):799-809. doi: 10.1001/archinternmed.2012.402.
4
Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality.
Arch Intern Med. 2012 May 28;172(10):811-7. doi: 10.1001/archinternmed.2012.1159.
5
Heart disease and stroke statistics--2010 update: a report from the American Heart Association.
Circulation. 2010 Feb 23;121(7):e46-e215. doi: 10.1161/CIRCULATIONAHA.109.192667. Epub 2009 Dec 17.
7
High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study.
Arch Intern Med. 2008 Nov 10;168(20):2219-24. doi: 10.1001/archinte.168.20.2219.
8
Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study.
J Am Coll Cardiol. 2008 Sep 30;52(14):1152-9. doi: 10.1016/j.jacc.2008.07.009.
9
Thyroid disease and the heart.
Circulation. 2007 Oct 9;116(15):1725-35. doi: 10.1161/CIRCULATIONAHA.106.678326.
10
Thyroid status, cardiovascular risk, and mortality in older adults.
JAMA. 2006 Mar 1;295(9):1033-41. doi: 10.1001/jama.295.9.1033.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验